EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	**Nicolas PITON**

Activities (2021 - 2025)	**Yes/No**	**Period (From - To)**	**Information**	**Details**
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: • **has a value of more than 10.000 EUR, or** • **entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of entity; • Place; • Type of entity: public, private.	[Please describe your role.]

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).
[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]
B. Consultancy, including advisory activities		05/2026	• Name of the entity; Roche • Place; Rouen, France • Type of the entity: private; Received amounts for remunerated activities ≃ 1000 €	I organized a webinar on ALK inmmunohistochemistry

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
		03/2026	• Name of the entity; AstraZeneca • Place; Rouen, France • Type of the entity: private; Received amounts for remunerated activities ≃ 516 €	Speaker during the "Journées d'échanges en biologie et anatomopathologie » on IA in thoracic pathology
		12/2025	• Name of the entity; Fujifilm • Place; Rouen, France • Type of the entity: private; Received amounts for remunerated activities ≃ 350 €	Speaker during the Fujifilm Workshop « Nodule pulmonaire périphérique »
		10/2025	Symposium of ALK immunohistochemistry Name of the entity; Roche Place; Paris, France Type of the entity: private; Received amounts for remunerated activities ≃ € 700	I participated in a scientific symposium on ALK immunohistochemistry

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities		10/2025	Ad-board anapaths GI & MEL - Name of the entity; Bristol Myers Squibb Place; Paris, France Type of the entity: private; Received amounts for remunerated activities ≃ € 578	I participated in a board of pathologists organized by Bristol Myers Squibb
	Yes ☒ No ☐	07/2025	If 'yes', please specify: Name of the entity; AstraZeneca Place; Paris, France Type of the entity: private; Received amounts for remunerated activities ≃ € 350	Speaker during the workshop « Diagnostic optimal » Fujufilm / AstraZeneca 2ième édition : Nodule pulmonaire périphérique : faites parler vos prélèvements ! Optimisation du diagnostic grâce à une meilleure collaboration avec vos pathologists.
		07/2025	• Name of the entity; Fujifilm • Place; Rouen, France • Type of the entity: private; • Received amounts for remunerated activities ≃ 800 €	Speaker during the Fujifilm European Workshop « Peripheral lung nodule » : How to optimize the characterization of peripheral pulmonary nodules by working hand in hand with your pathologist.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
		2024	• Name of the entity; Bristol Myers Squibb • Place; Paris, France • Type of the entity: private; Received amounts for remunerated activities = 1535 €	Participant in 2 “boards” on lung cancer and pleural mesothelioma
		2024	• Name of the entity; MSD France • Place; Rouen, France • Type of the entity: private; Received amounts for remunerated activities = 622 €	Speaker during the MSD wokshop « Actualités dans la prise en charge des CBNPC » : *Évaluation de la réponse pathologique et nouvelles stratégies anatomo-chirurgicales à l’ère des traitements néoadjuvants efficaces*
		2024	• Name of the entity; AstraZeneca • Place; Paris, France • Type of the entity: private; Received amounts for remunerated activities ≃ 850 €	Speaker during the first workshop « Diagnostic optimal » Fujufilm / AstraZeneca 1er édition: Optimisation des prélèvements ; les attentes du pathologiste

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
		2024	• Name of the entity; AstraZeneca • Place; Paris, France • Type of the entity: private; Received amounts for remunerated activities ≃ 800 €	Speaker during the scientific meeting organized by AstraZeneca : Journées d'Échanges en BioPathologie
		2023	• Name of the entity; AstraZeneca • Place; Rouen, France • Type of the entity: private; Received amounts for remunerated activities ≃ 2723 €	Speaker during the AstraZeneca meetings: - Réunion scientifique AstraZeneca : CBNPC stade précoce résécable : le point de vue du pathologiste (2023) - Réunion scientifique AstraZeneca : Journées d'Échanges en BioPathologie (2023) • MMR vs MSI • Optimisation du testing en routine dans le cancer du poumon : quel test dans quel ordre ?

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
		2022	• Name of the entity; Boehringer Ingelheim • Place; Le Havre, France • Type of the entity: private; Received amounts for remunerated activities ≃ 582 €	Speaker during the Boehringer–Ingelheim meeting : Évolution : Fibrose pulmonaire (2022)
		2022	• Name of the entity; AstraZeneca • Place; Paris, France • Type of the entity: private; Received amounts for remunerated activities ≃ 424 €	Speaker during AstraZeneca : Journées d'Échanges en BioPathologie – CBNPC métastatique : Quelle prise en charge pour le patient aujourd'hui ?
		2021	• Name of the entity; Takeda • Place; Rouen, France • Type of the entity: private; Received amounts for remunerated activities ≃ 496 €	Speaker during the Takeda workshop: Échange de pratiques cliniques autour de la prise en charge des patients atteints de cancers bronchiques non à petites cellules (CBNPC) ALK+ et EGFR exon 20
C. Non-remunerated post	Yes ☒ No ☐	12/2025 – 03/2026	• INCA (french national institute of cancer), public	Reviewer for the French National Institute of Cancer for the national guidelines of lung cancer

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
		12/2025-now	• Treasurer of the association AFPC (Association française de Pathologie computationnel)	AFPC is a non-profit academic association dedicated to computational pathology
		11/2025-now	• Deputy treasurer of the association SFP (Société française de Pathologie)	SFP is a non-profit academic association gathering medical pathologists
D. Legal representation[5]	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	MM/YYYY – MM/YYYY	Arhant, G ; Lachkar, S ; Thiebaut, PA ; Marguet, F ; Lamy, A ; Thiberville, L ; Salaün, M ; Guisier, F ; Sabourin, JC ; Piton, N,. *Detection of Tumor DNA in Bronchoscopic Fluids in Peripheral NSCLC: A Proof-of-Concept Study.*. **JTO Clin Res Rep.** 2024, 5. Catégorie : C ; IF = 3 Lachkar, S ; Faur, Q ; Marguet, F ; Veresezan, L ; Bubenheim, M ; Salaün, M ; Thiberville, L ; Sabourin, JC ; Guisier, F ; Piton, N. *Assessment of endobronchial ultrasound-guided bronchoscopy (EBUS) intranodal forceps biopsy added to EBUS 19-gauge transbronchial needle aspiration: A blinded pathology panel*	Researcher

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
			analysis. **Thorac Cancer**, 2023, 14, 2149-2157 Catégorie : C ; IF = 2,3 Haddad, E ; Bottet, B ; Thiebaut, PA ; Morin, S ; Dreyfus, H ; Vannier, É ; Vincent, V Marguet, F ; Lamy, A ; Sobol, H ; Baste, JM ; Guisier, F ; Sabourin, JC ; Piton, N , *Squamous Cell Carcinoma of the Lung With Microsatellite Instability in a Patient With Lynch Syndrome: A Case Report*. **JTO Clin Res Rep**, 2024, 5 Catégorie : C ; IF = 3	

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Type of received support: grants, funds; • Entity which offered the support: name, place, type (public, private); • Received amounts (for public grants please also specify the annual budget of your home institution).	[Please mention the title of the studies you refer to.]
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	2021 – now	• Name, European Society of Pathology working groups on Molecular Pathology, Pulmonary Pathology and Thymic and Mediastinal Pathology • Place; / • Type: public	Member of the working groups.
		From 2020 to now	• Expert in the national network INCa MESOPATH (mesothelioma)	

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).
[7] **Organisation** refers to a governmental, international or non-profit organisation.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
		From 2018 to now	• Expert in the national network INCa RYTHMIC (thymic malignancies)	
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the activity.	[Please describe the activity.]

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname: **Prof. Nicolas PITON** **Date: 07/07/2026**



Signature: **Place: Rouen, FRANCE**

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656
[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.
[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725